Dr. Hallenbeck will provide an update on the benefits and challenges of multiple intravenous delivery of oncolytic viruses
PHILADELPHIA–(BUSINESS WIRE)–Seneca Therapeutics, Inc. (STI), announced today that Dr. Paul Hallenbeck will present a talk at the 8th Oncolytic Virotherapy Summit 2023 entitled “Assessing the Benefits and Challenges of Intravenous Delivery of Oncolytic Viruses”. In his talk, Dr. Hallenbeck will discuss the challenges inherent in doing multiple (IV) intravenous administrations of oncolytic viruses, where the field is meeting these challenges, and present data on the development of multiple IV technology for STI’s oncolytic virus SVV-001, a clinical stage oncology product.
“There are several important hurdles to be overcome to develop the capability of performing multiple intravenous delivery of an oncolytic virus,” said Dr. Paul Hallenbeck, President and Chief Scientific Officer at Seneca Therapeutics. “These include cost of goods, high cancer target selectivity, elimination and/or avoidance of existing neutralizing antibodies and obtaining significant replication at the tumor site. SVV-001 has the profile to potentially meet all these multiple challenges.”
About Seneca Therapeutics
Seneca Therapeutics was founded to capitalize on the profound tumor specificity of SVV and further the development of SVV-001 in several upcoming clinical trials and the creation and testing of armed derivatives selectively expressing gene product(s) that are inserted into the genome of SVV-001 that create additional anti-tumor effects.
This press release contains “forward-looking statements” concerning the development of Seneca Therapeutics products, the potential benefits and attributes of those products, and the company’s expectations regarding its prospects. Forward-looking statements are subject to risks, assumptions and uncertainties that could cause actual future events or results to differ materially from such statements. These statements are made as of the date of this press release. Actual results may vary. Seneca Therapeutics undertakes no obligation to update any forward-looking statements for any reason.
CSO and President